Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 10/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12714672 | 1.00 | TYMP (0.59) | TYMPKDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL3821714 | 1.00 | TYMP (0.59) | TYMPKDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL21828784 | 1.00 | TYMP (0.59) | TYMPKDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL31556051 | 1.00 | TYMP (0.59) | TYMPKDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL31093208 | 0.94 | TYMP (0.51) | TYMPKDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL29799112 | 0.93 | KDM4E (0.52) | TYMPKDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL3820892 | 0.92 | KDM4E (0.56) | TYMPKDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL31342955 | 0.92 | TYMP (0.61) | TYMPKDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL32677371 | 0.90 | TYMP (0.58) | TYMPKDM4EPOLA1TAS1R3TAS1R1 | |
| SCHEMBL9017501 | 0.90 | TYMP (0.58) | TYMPKDM4EPOLA1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107099004-B | A kind of fluorescence hydrogel of high intensity and preparation method thereof | 河南理工大学 | 2019-08-16 | — | — | CN | claimed |
| CN-107099004-A | A kind of fluorescence hydrogel of high intensity and preparation method thereof | 河南理工大学 | 2017-08-29 | — | — | CN | claimed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4640693-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-20250313591-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-10-09 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12337291-B2 | Guide RNA synthesis system and method | SYNTHEGO CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-12269841-B2 | Production method for oligonucleotides | AJINOMOTO CO., INC. (JP) | 2025-04-08 | — | — | US | disclosed |
| US-5132418-A | On modified silica support | UNIVERSITY PATENTS, INC. (US) | 1992-07-21 | — | — | US | disclosed |
| EP-0035719-B1 | PROCESS FOR PRODUCING MODIFIED INORGANIC POLYMERS, THEIR USE IN PRODUCING POLYNUCLEOTIDES, AND A REAGENT USEFUL IN THESE PROCESSES | UNIVERSITY PATENTS, INC. (US) | 1989-09-20 | — | — | EP | disclosed |
| US-4835263-A | Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis and their use | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1989-05-30 | — | — | US | disclosed |
| EP-0117777-B1 | COMPOUNDS CONTAINING AN OLIGONUCLEOTIDE BONDED TO AN INTERCALLATING AGENT, A PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1987-12-23 | — | — | EP | disclosed |
| US-4500707-A | Nucleosides useful in the preparation of polynucleotides | UNIVERSITY PATENTS, INC. (US) | 1985-02-19 | — | — | US | disclosed |
| EP-0102995-A1 | POLYNUCLEOTIDE SYNTHESIS | CELLTECH LIMITED (GB) | 1984-03-21 | — | — | EP | disclosed |
| EP-0097805-A2 | Nucleoside phosphite compounds | UNIVERSITY PATENTS, INC. (US) | 1984-01-11 | — | — | EP | disclosed |
| WO-1983003098-A1 | POLYNUCLEOTIDE SYNTHESIS | EATON, MICHAEL, ANTHONY, WILLIAM | 1983-09-15 | — | — | WO | disclosed |
| EP-0035719-A2 | Process for producing modified inorganic polymers, their use in producing polynucleotides, and a reagent useful in these processes | UNIVERSITY PATENTS, INC. (US) | 1981-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | TYMP 80/4885KDM4E 3277/4885POLA1 49/4885 |
| US-20250313591-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | POLRMT, COASY, RNGTT | TYMP 152/4885KDM4E 2781/4885POLA1 77/4885 |
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | TYMP 149/4885KDM4E 3231/4885POLA1 31/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | TYMP 2728/4885KDM4E 4623/4885POLA1 4570/4885 |
| US-12492217-B2 | Reagents and their use for modular enantiodivergent synthesis of C—P bonds | PNKP, POLL, RNGTT | TYMP 51/4885KDM4E 3574/4885POLA1 138/4885 |
| US-12269841-B2 | Production method for oligonucleotides | RNGTT, DCLRE1B, PHOSPHO1 | TYMP 30/4885KDM4E 2580/4885POLA1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.